{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-123289","form_type":"8-K","ticker":"DSGN","cik":"0001807120","company_name":"Design Therapeutics, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.717517+00:00","generated_at":"2026-05-30T03:45:17.806010+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Design Therapeutics Q3 net loss $13.0M; FECD Phase 1 trial initiated, data H1 2025","bullets":["Net loss of $13.0M for Q3 2024; R&D expense $11.9M, G&A expense $4.4M.","Cash and securities $254.1M as of Sep 30, 2024; expected to fund operations into 2029.","FECD DT-168 Phase 1 trial initiated in healthy volunteers; initial data expected H1 2025.","FA DT-216P2 Phase 1 single ascending dose study in healthy volunteers on track for H1 2025.","Preclinical programs advancing toward development candidate selection in HD and DM1."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-123289","json":"https://secwatch.observer/filing/0000950170-24-123289.json","markdown":"https://secwatch.observer/filing/0000950170-24-123289.md","text":"https://secwatch.observer/filing/0000950170-24-123289.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1807120/000095017024123289/0000950170-24-123289-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1807120/000095017024123289/dsgn-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:45:17.806010+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}